Study:
Adjuvant Chemo-RT With Cisplatin (NSC-119875) and Docetaxel (NSC-628503) After Complete Resection of Locally Advanced (Stage III and IV) Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Rationale:
Drugs used in chemotherapy, such as cisplatin and docetaxel, work in different
ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses
high-energy x-rays to damage tumor cells. Cisplatin and docetaxel may make the tumor cells
more sensitive to radiation therapy. Giving chemoradiotherapy after surgery may kill any
remaining tumor cells.
Purpose:
This phase II trial is studying how well adjuvant chemoradiotherapy using cisplatin
and docetaxel works in treating patients with completely resected stage III or stage IV head
and neck cancer.
Study Status: Withdrawn
Recruiting:
n/a
| Condition |
Intervention |
Phase |
|
Head and Neck Cancer |
Drug: cisplatin
Drug: docetaxel
Radiation: radiation therapy |
Phase 2 |
Verified by
Southwest Oncology Group
June, 2012
Sponsored by: Southwest Oncology Group
Information provided by: Southwest Oncology Group
ClinicalTrials.gov identifier: NCT00084435
Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States
Community Oncology Group at Cleveland Clinic Cancer Center
Independence, Ohio 44131
United States
Cleveland Clinic - Wooster
Wooster, Ohio 44691
United States
Prakash C. Neupane, MD., Principal Investigator
Harold E. Kim, MD., Study Chair
Stephen K. Williamson, MD., Study Chair
George H. Yoo, MD., Study Chair